Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...
Novo Nordisk’s next-gen medication is called CagriSema. It’s a once-weekly shot that combines a long-acting amylin analogue ...
14hon MSN
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback